OncoCyte Corporation (OCX)
NASDAQ: OCX · Real-Time Price · USD
2.750
+0.200 (7.84%)
Nov 20, 2024, 4:00 PM EST - Market closed
OncoCyte Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 0.71 | 1.5 | 0.96 | 2.2 | 1.22 | - | Upgrade
|
| Revenue Growth (YoY) | -51.54% | 56.89% | -56.41% | 80.76% | - | - | Upgrade
|
| Cost of Revenue | 0.59 | 1 | 0.88 | 0.7 | 1.86 | - | Upgrade
|
| Gross Profit | 0.12 | 0.5 | 0.08 | 1.5 | -0.64 | - | Upgrade
|
| Selling, General & Admin | 12.78 | 13.54 | 21.53 | 20.39 | 22.45 | 15.45 | Upgrade
|
| Research & Development | 10.13 | 9.15 | 7.28 | 4.8 | 9.43 | 6.79 | Upgrade
|
| Operating Expenses | 23 | 22.77 | 28.91 | 25.28 | 31.87 | 22.24 | Upgrade
|
| Operating Income | -22.88 | -22.27 | -28.83 | -23.77 | -32.51 | -22.24 | Upgrade
|
| Interest Expense | -0.2 | -0.05 | -0.08 | -0.21 | -0.25 | - | Upgrade
|
| Interest & Investment Income | - | - | - | - | - | 0.3 | Upgrade
|
| Earnings From Equity Investments | - | - | - | -0.27 | -1.55 | -0.28 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.72 | 0.39 | -0.06 | -0.04 | 0.03 | -0 | Upgrade
|
| EBT Excluding Unusual Items | -22.36 | -21.93 | -28.98 | -24.29 | -34.29 | -22.22 | Upgrade
|
| Merger & Restructuring Charges | -0.58 | -0.59 | -1.5 | -2.69 | -1.21 | - | Upgrade
|
| Impairment of Goodwill | - | - | -18.68 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.07 | -0.06 | -0.47 | 0.23 | 0.3 | -0.05 | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.28 | -1.28 | - | - | - | - | Upgrade
|
| Asset Writedown | 1.12 | -6.76 | - | - | - | - | Upgrade
|
| Other Unusual Items | -19.97 | 5.76 | 31.02 | -26.13 | 4.01 | -0.15 | Upgrade
|
| Pretax Income | -43.14 | -24.86 | -18.61 | -52.87 | -31.19 | -22.43 | Upgrade
|
| Income Tax Expense | - | - | - | -9.26 | -1.25 | - | Upgrade
|
| Earnings From Continuing Operations | -43.14 | -24.86 | -18.61 | -43.61 | -29.93 | -22.43 | Upgrade
|
| Earnings From Discontinued Operations | - | -2.93 | -54.29 | -20.49 | - | - | Upgrade
|
| Net Income | -43.14 | -27.78 | -72.9 | -64.1 | -29.93 | -22.43 | Upgrade
|
| Preferred Dividends & Other Adjustments | 0.2 | 0.94 | 0.52 | - | - | - | Upgrade
|
| Net Income to Common | -43.35 | -28.72 | -73.42 | -64.1 | -29.93 | -22.43 | Upgrade
|
| Shares Outstanding (Basic) | 11 | 8 | 6 | 4 | 3 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 8 | 6 | 4 | 3 | 3 | Upgrade
|
| Shares Change (YoY) | 52.77% | 38.10% | 24.61% | 35.80% | 27.65% | 35.52% | Upgrade
|
| EPS (Basic) | -4.02 | -3.75 | -13.25 | -14.42 | -9.14 | -8.74 | Upgrade
|
| EPS (Diluted) | -4.04 | -3.75 | -13.25 | -14.42 | -9.14 | -8.74 | Upgrade
|
| Free Cash Flow | -21.86 | -23.61 | -49.91 | -38.19 | -27.21 | -20.63 | Upgrade
|
| Free Cash Flow Per Share | -2.03 | -3.09 | -9.01 | -8.59 | -8.31 | -8.04 | Upgrade
|
| Gross Margin | 16.36% | 33.33% | 8.14% | 68.29% | -52.55% | - | Upgrade
|
| Operating Margin | -3227.36% | -1481.57% | -3009.50% | -1081.62% | -2673.77% | - | Upgrade
|
| Profit Margin | -6113.82% | -1911.04% | -7664.09% | -2916.15% | -2461.51% | - | Upgrade
|
| Free Cash Flow Margin | -3083.07% | -1570.59% | -5209.60% | -1737.40% | -2237.42% | - | Upgrade
|
| EBITDA | -21.56 | -20.59 | -23.61 | -19.57 | -32.12 | -21.9 | Upgrade
|
| D&A For EBITDA | 1.33 | 1.68 | 5.22 | 4.21 | 0.39 | 0.34 | Upgrade
|
| EBIT | -22.88 | -22.27 | -28.83 | -23.77 | -32.51 | -22.24 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.